| 词条 | Silodosin |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | UNII_Ref = {{fdacite|correct|FDA}} | UNII = CUZ39LUY82 | verifiedrevid = 464390579 | IUPAC_name = 1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]indoline-7-carboxamide | image = silodosin.png | synonyms = KAD-3213, KMD-3213 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 4471557 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 24778 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = PNCPYILNMDWPEY-QGZVFWFLSA-N | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 160970-54-7 | ATC_prefix = G04 | ATC_suffix = CA04 | PubChem = 5312125 | IUPHAR_ligand = 493 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | C = 25 |H = 32 |F = 3 |N = 3 |O = 4 | molecular_weight = 495.534 g/mol | smiles = FC(F)(F)COc3ccccc3OCCN[C@H](C)Cc1cc2c(c(c1)C(=O)N)N(CC2)CCCO | bioavailability = 32% | protein_bound = 97% | metabolism = Hepatic glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement | elimination_half-life = 13±8 hours | excretion = Renal and fecal | pregnancy_US = B | pregnancy_category = Not approved for use in women | licence_EU = yes | legal_status = Rx-only | routes_of_administration = Oral }} Silodosin (trade names Rapaflo (USA), Silodyx (Europe and South Africa), Rapilif (India), Silodal (India), Sildoo(India) Urief (Japan), Thrupas (South Korea), Urorec (Russia) is a medication for the symptomatic treatment of benign prostatic hyperplasia. It acts as an α1-adrenoceptor antagonist with high uroselectivity (selectivity for the prostate). HistorySilodosin received its first marketing approval in Japan in May 2006 under the tradename Urief, which is jointly marketed by Kissei Pharmaceutical Co., Ltd. and Daiichi Sankyo Pharmaceutical Co., Ltd. Kissei licensed the US, Canadian, and Mexican rights for silodosin to Watson Pharmaceuticals, Inc. in 2004. FDA approved silodosin on October 9, 2008.[1] Silodosin is marketed under the trade names Rapaflo in the US and Silodyx in Europe.[2] PharmacologySince silodosin has high affinity for the α1A adrenergic receptor, it causes practically no orthostatic hypotension (in contrast to other α1 blockers). On the other side, the high selectivity seems to be the cause of silodosin's typical side effect of loss of seminal emission.[3] As α1A adrenoceptor antagonists are being investigated as a means to male birth control due to their ability to inhibit ejaculation but not orgasm, a trial with 15 male volunteers was conducted. While silodosin was completely efficacious in preventing the release of semen in all subjects, 12 out of the 15 patients reported mild discomfort upon orgasm. The men also reported the psychosexual side effect of being strongly dissatisfied by their lack of ejaculation.[4] References1. ^{{cite web |url=https://www.drugs.com/nda/silodosin_080212.html |title=Drugs.com, Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia |accessdate=2008-02-13 |work= }} 2. ^European Medicines Agency: Assessment report for Silodyx 3. ^{{cite journal |pmc=2834370|year=2009|author1=Kobayashi|first1=K|title=Orgasm is preserved regardless of ejaculatory dysfunction with selective α1A-blocker administration|journal=International Journal of Impotence Research|volume=21|issue=5|pages=306–310|last2=Masumori|first2=N|last3=Kato|first3=R|last4=Hisasue|first4=S|last5=Furuya|first5=R|last6=Tsukamoto|first6=T|doi=10.1038/ijir.2009.27|pmid=19536124}} 4. ^{{cite journal |vauthors=Kobayashi K, Masumori N, Kato R, Hisasue S, Furuya R, Tsukamoto T |title=Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration. |journal=Int J Impot Res. |volume=21 |issue=5 |pages=306–10 |date=December 2009 |pmid=19536124 |pmc=2834370 | doi = 10.1038/ijir.2009.27 }} External links
8 : Alpha blockers|Phenethylamines|Phenol ethers|Indolines|Organofluorides|Benzamides|Alcohols|Trifluoromethyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。